Author

J. Velez

Institution: Duke University

Observed institutions: Amgen (United States), Duke University, Genentech, University of Alabama at Birmingham, University of California San Francisco Medical Center, Childhood Arthritis and Rheumatology Research Alliance

OpenAlex ID: A5090128429

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

2022 · Timothy Beukelman, George Tomlinson, et al. · Pediatric Rheumatology · 24

Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry

2022 · Jessica Neely, Kaveh Ardalan, et al. · Pediatric Rheumatology · 15

Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis

2021 · Nayimisha Balmuri, William Daniel Soulsby, et al. · Pediatric Rheumatology · 14

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

2022 · Timothy Hahn, Carrie Daymont, et al. · Pediatric Rheumatology · 10

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

2021 · Timothy Beukelman, Aimee Lougee, et al. · Pediatric Rheumatology · 5

Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research

2024 · Margaret H. Chang, Fatima Barbar-Smiley, et al. · Pediatric Rheumatology · 1

Works count: 6

Citation count: 69

H-index: 5

I10-index: 4